Glucocorticoid Sensitivity and Proinflammatory Cytokines Pattern in Pemphigus


Autoria(s): Chriguer, Rosangela Soares; Roselino, Ana Maria; Castro, Margaret de
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

24/09/2013

24/09/2013

01/08/2012

Resumo

Glucocorticoids (GC) represent the main treatment for pemphigus; however, some patients show GC resistance. GC sensitivity was evaluated in 19 pemphigus patients and 41 controls by the number of binding sites [B-max (fmol/mg protein)] and the affinity of GC receptor [Kd (nM)] to dexamethasone (DEX) as well as by the pattern of cytokine by DEX-mediated inhibition of concanavalin-A (Con-A)-stimulated PBMC proliferation. The Kd (15.7 +/- 2.8 vs.8.1 +/- 1.3) and Bmax (6.5 +/- 0.9 vs. 3.9 +/- 0.3) were higher in pemphigus than controls (p = 0.002). Considering the values above the 95th percentile of normal group as a cut-off (K-d > 24.9 nM and B-max > 8.1 fmol/mg protein), elevated K-d and B-max were observed in 9.8% and 2.4% of controls and 15.8% and 36.8% of patients (p = 0.02). PBMC proliferation was stimulated by Con-A and inhibited by DEX (p < 0.001) in both pemphigus and control groups. IL-6 and TNF alpha (pg/mL) basal production were higher in patients than controls. There was an increment of these cytokines after Con-A stimulation, and they were inhibited by DEX (p = 0.002) in controls and remained elevated in pemphigus (p < 0.02). Patients and controls showed no difference in basal and stimulated production of IL-8 and IL-10. There is an alteration on GC sensitivity in pemphigus patients and a higher production of proinflammatory cytokines. Therefore, in pemphigus patients, proinflammatory cytokines might be involved in the mechanism of GC resistance and/or in its maintenance.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [03/09857-0]

CNPq [151925/2007-0]

CNPq

Identificador

JOURNAL OF CLINICAL IMMUNOLOGY, NEW YORK, v. 32, n. 4, pp. 786-793, AUG, 2012

0271-9142

http://www.producao.usp.br/handle/BDPI/33643

10.1007/s10875-012-9679-y

http://dx.doi.org/10.1007/s10875-012-9679-y

Idioma(s)

eng

Publicador

SPRINGER/PLENUM PUBLISHERS

NEW YORK

Relação

JOURNAL OF CLINICAL IMMUNOLOGY

Direitos

openAccess

Copyright SPRINGER/PLENUM PUBLISHERS

Palavras-Chave #PEMPHIGUS #GLUCOCORTICOID RECEPTOR #GLUCOCORTICOID SENSITIVITY #CYTOKINES #FOLIACEUS FOGO SELVAGEM #NATURAL-KILLER-CELLS #RECEPTOR-BETA #CLINICAL-IMPLICATIONS #RHEUMATOID-ARTHRITIS #HUMAN AUTOANTIBODIES #IN-VITRO #VULGARIS #THERAPY #EXPRESSION #IMMUNOLOGY
Tipo

article

original article

publishedVersion